For the decades-long question of what actually triggers multiple sclerosis relapses, this Nature Medicine study offers a mechanistically specific and potentially actionable answer. Understanding what precedes an MS attack — not just what causes the disease — could transform how clinicians monitor and pre-empt flares in millions of patients worldwide.
The research identifies a temporal immune signature in peripheral blood that reliably precedes clinical MS relapses. Specifically, investigators found that upregulation of Epstein-Barr virus reactivation genes within B cells — combined with elevated expression of MS-associated risk genes that are known transcriptional targets of the EBV latency protein EBNA-2 — occurred in the weeks before patients experienced neurological attacks. This dual signal, linking viral reactivation to genetically encoded susceptibility pathways, was detectable in circulating immune cells rather than requiring central nervous system sampling, making it potentially translatable to clinical surveillance.
This finding sits at the intersection of two previously parallel bodies of research: the established but mechanistically incomplete epidemiological link between EBV infection and MS risk, and the genomic evidence that EBNA-2 binds and dysregulates a disproportionate number of MS susceptibility loci. What is new here is the prospective, longitudinal dimension — showing that the virus isn't just a historical trigger but an active, recurring participant in relapse biology. This elevates EBV from a background risk factor to a dynamic disease-modifying agent.
The implications are considerable but require measured interpretation. Whether this B cell gene expression pattern constitutes a reliable predictive biomarker across diverse MS subtypes and treatment backgrounds remains to be validated in larger, multicenter cohorts. The study also raises urgent questions about whether antiviral interventions timed to suppress EBV reactivation could blunt relapse frequency — a hypothesis that several ongoing clinical trials are beginning to address. If replicated, this work is genuinely paradigm-shifting for how MS relapse biology is understood.